Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach.
Colorectal neoplasms
Microsatellite instability
Next-generation sequencing
Precision medicine
Journal
World journal of clinical oncology
ISSN: 2218-4333
Titre abrégé: World J Clin Oncol
Pays: United States
ID NLM: 101549149
Informations de publication
Date de publication:
24 Nov 2021
24 Nov 2021
Historique:
received:
24
06
2021
revised:
11
08
2021
accepted:
19
09
2021
entrez:
15
12
2021
pubmed:
16
12
2021
medline:
16
12
2021
Statut:
ppublish
Résumé
The identification of several genetic mutations in colorectal cancer (CRC) has allowed a better comprehension of the prognosis and response to different antineoplastic treatments. Recently, through a systematic process, consensus molecular subtypes (CMS) have been described to characterize genetic and molecular mutations in CRC patients. Through CMS, CRC patients can be categorized into four molecular subtypes of CRC by wide transcriptional genome analysis. CMS1 has microsatellite instability and mutations in CIMP and BRAF pathways. CMS2, distinguished by mutations in specific pathways linked to cellular metabolism, also has a better prognosis. CMS3 has a KRAS mutation as a hallmark. CMS4 presents mutations in fibrogenesis pathways and mesenchymal-epithelial transition, associated with a worse prognosis. CMS classification can be a meaningful step in providing possible answers to important issues in CRC, such as the use of adjuvant chemotherapy in stage II, personalized first-line chemotherapy for metastasic CRC, and possible new target treatments that address specific pathways in each molecular subtype. Understanding CMS is a crucial step in personalized medicine, although prospective clinical trials selecting patients by CMS are required to pass proof-of-concept before becoming a routine clinical tool in oncology routine care.
Identifiants
pubmed: 34909395
doi: 10.5306/wjco.v12.i11.1000
pmc: PMC8641009
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1000-1008Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Références
Pathobiology. 2018;85(1-2):72-84
pubmed: 29414818
Int J Cancer. 2014 Feb 1;134(3):552-62
pubmed: 23852808
Oncology. 2020;98(8):534-541
pubmed: 32235113
Ann Oncol. 2018 May 1;29(5):1227-1234
pubmed: 29518181
Ann Oncol. 2013 Oct;24 Suppl 6:vi64-72
pubmed: 24078664
J Pathol. 2013 Feb;229(3):441-8
pubmed: 23165447
Visc Med. 2019 Aug;35(4):259-264
pubmed: 31602389
Cancers (Basel). 2020 Jan 30;12(2):
pubmed: 32019056
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Pathol Res Pract. 2021 Apr;220:153379
pubmed: 33721619
Semin Oncol. 2011 Aug;38(4):511-20
pubmed: 21810510
Cancer Treat Rev. 2017 Jun;57:1-7
pubmed: 28505475
BMC Cancer. 2019 Nov 27;19(1):1155
pubmed: 31775679
PLoS Med. 2013;10(5):e1001453
pubmed: 23700391
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Virchows Arch. 2016 Aug;469(2):125-34
pubmed: 27325016
Medicine (Baltimore). 2020 Jun 19;99(25):e20617
pubmed: 32569190
Oncotarget. 2018 Apr 10;9(27):18698-18711
pubmed: 29721154
J Natl Compr Canc Netw. 2018 Apr;16(4):359-369
pubmed: 29632055
Oncologist. 2020 Dec;25(12):e1968-e1979
pubmed: 32926498
ESMO Open. 2021 Apr;6(2):100073
pubmed: 33676295
Br J Cancer. 2013 Apr 30;108(8):1757-64
pubmed: 23511557
J Clin Oncol. 2019 Aug 1;37(22):1876-1885
pubmed: 31042420
Sci Rep. 2017 Nov 30;7(1):16618
pubmed: 29192179
Ann Oncol. 2018 Nov 1;29(11):2240-2246
pubmed: 30247524
Gastroenterology. 2010 Jun;138(6):2163-76
pubmed: 20420953
Sci Rep. 2020 Jul 21;10(1):12123
pubmed: 32694712
Curr Drug Targets. 2018;19(15):1731-1737
pubmed: 30073926
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Genes Dis. 2019 Oct 30;8(2):133-145
pubmed: 33997160
Ann Oncol. 2019 Nov 1;30(11):1796-1803
pubmed: 31868905
Oncol Lett. 2020 Feb;19(2):1487-1495
pubmed: 31966075
Clin Cancer Res. 2017 Jan 15;23(2):387-398
pubmed: 27459899
Oncoimmunology. 2018 Feb 14;7(5):e1426519
pubmed: 29721396
Acta Oncol. 2015 Jan;54(1):5-16
pubmed: 25430983
Methods Mol Biol. 2018;1765:179-191
pubmed: 29589308
Clin Gastroenterol Hepatol. 2016 May;14(5):651-8
pubmed: 26872400
JAMA Oncol. 2016 Sep 1;2(9):1162-9
pubmed: 27270348
Gastroenterology. 2013 Aug;145(2):348-56.e1-2
pubmed: 23665275
Lancet Oncol. 2019 May;20(5):e274-e283
pubmed: 31044725
Crit Rev Oncol Hematol. 2017 Jan;109:9-19
pubmed: 28010901
Curr Gastroenterol Rep. 2019 Jan 30;21(2):5
pubmed: 30701321
Semin Cancer Biol. 2019 Apr;55:37-52
pubmed: 29775690
Ann Oncol. 2019 Apr 1;30(4):520-527
pubmed: 30796810
Clin Gastroenterol Hepatol. 2019 Feb;17(3):402-410.e2
pubmed: 29306042
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32079617
Nat Rev Cancer. 2017 Feb;17(2):79-92
pubmed: 28050011